

Special Issue

Classification, Risk Assessment and Clinical Management of Malignant Thyroid Nodules

Message from the Guest Editors

As is already known, thyroid nodules usually occur in the general population and differentiating between benign and malignant ones is still a challenge. The basic tests for the risk stratification of thyroid nodules comprise serum TSH, ultrasonography (US), and fine-needle aspiration (FNA), which are the baseline in general practice, with radionuclide scans performed only for patients with low TSH. Assessing the risk of malignancy of thyroid nodules with US is crucial, as it can support in the selection of those who should undergo fine-needle aspiration (FNA) and subsequent surgery. Several reports identified a few US features that are remarkably more frequent in malignant thyroid nodules, which can be merged to be used as indicators of high risk. As pediatric surgeons, huge effort has been made to understand how age is a crucial factor in patient outcome: while thyroid nodules are much more common in adults, they are much more likely to be malignant in children, resulting in a better outcome.

Guest Editors

Prof. Dr. Claudio Spinelli

Division of Pediatric Surgery, Department of Surgical Pathology, University of Pisa, 56126 Pisa, Italy

Dr. Marco Ghionzoli

Division of Pediatric Surgery, Department of Surgical Pathology, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions

30 November 2024



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/182165

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)